The Role of Caldesmon CaD, Integrin αV, Tissue Inhibitor of Metalloproteinases TIMP-1 in Molecular Mechanisms of Pulmonary Tuberculosis Development

The objective: to study the role of CaD proteins, αV integrin and TIMP-1 in the development of pulmonary tuberculosis.

Subjects and Methods. 27 specimens of pulmonary tuberculomas were used for this study. The specimens were divided into 3 goups in accordance with the degree of inflammatory and reparative changes occurring in the tuberculoma tissue. The targeting proteins were visualized by immunohistochemical methods. For quantification, the relative area of expression of signaling molecules was counted. The obtained data were statistically processed based on nonparametric criteria.

Results. Data analysis showed an increased level of CaD expression during wall epithelialisation compared to the group with no connective tissue repair, which was associated with the involvement of CaD in the concomitant repair and fibrosis formation. Statistically significant differences in the expression levels of αV integrin between Groups 2 and 3 were found in the case of granuloma inflammation. The decrease in the protein levels from Group 2 to Group 3 may be due to activation of the anti-inflammatory mediator TGFβ1 and induction of M2 macrophages. The results of testing TIMP-1 expression level demonstrated its involvement both in granuloma fibrosis and formation of connective tissue complex in the inflammation site. The obtained data indicate that the studied proteins can be considered as informative biomarkers in molecular diagnostics and assessment of prognosis of pulmonary tuberculosis development.

1. Paltsev M.A., Anichkov N.M., Rybakova M.G. Rukovodstvo k prakticheskim zanyatiyam po patologicheskoy anatomii. [Guide to practical classes in pathological anatomy]. Moscow, Meditsina Publ., 2002, 896 p.

2. Samsonov K.Yu., Mordyk A.V., Aroyan A.R., Batischeva T.L., Ivanova O.G. Reparation of lung tissue in newly detected pulmonary tuberculosis as genetically determined process. Tuberculosis and Lung Diseases, 2020, vol. 98, no. 8, pp. 7-13. (In Russ.) https://doi.org/10.21292/2075-1230-2020-98-8-7-13

3. Allard B., Panariti A., Martin J.G. Alveolar macrophages in the resolution of inflammation, tissue repair, and tolerance to infection. Frontiers in Immunology, 2018, vol. 9, pp. 1777. https://doi.org/10.3389/fimmu.2018.01777

4. Brown N.F., Marshall J.F. Integrin-mediated TGFβ activation modulates the tumour microenvironment. Cancers, 2019, vol. 11, no. 9, pp. 1221. https://doi.org/10.3390/cancers11091221

5. Datta M., Via L.E., Kamoun W.S. et al. Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery. Proceedings of the National Academy of Sciences, 2015, vol. 112, no. 6, pp. 1827-1832. https://doi.org/10.1073/pnas.1424563112

6. Grünwald B., Schoeps B., Krüger A. Recognizing the molecular multifunctionality and interactome of timp-1. Trends in Cell Biology, 2019, vol. 29, no. 1, pp. 6-19. https://doi.org/10.1016/j.tcb.2018.08.006

7. Hegmann T.E., Schulte D.L., Lin J.L., Lin J.J. Inhibition of intracellular granule movement by microinjection of monoclonal antibodies against caldesmon. Cell Motility and the Cytoskeleton, 1991, vol. 20, no. 2, pp. 109-120. https://doi.org/10.1002/cm.970200204

8. Hynes R.O. Integrins: bidirectional, allosteric signaling machines. Cell, 2002, vol. 110, no. 6, pp. 673-687. https://doi.org/10.1016/s0092-8674(02)00971-6

9. Jackson H.W., Defamie V., Waterhouse P., Khokha R. TIMPs: versatile extracellular regulators in cancer. Nature Reviews Cancer, 2017, vol. 17, no. 1, pp. 38-53. https://doi.org/10.1038/nrc.2016.115

10. Jiang D., Xiaoxi Huang, Jing Geng, Run Dong, Shuhong Li, Zheng Liu, Chen Wang, Huaping Dai. Pulmonary fibrosis in a mouse model of sarcoid granulomatosis induced by booster challenge with Propionibacterium acnes. Oncotarget., 2016, vol. 7, no. 23, pp. 33703-33714. https://doi.org/10.18632/oncotarget.9397

11. Kelly A., Gunaltay S., McEntee C.P., Shuttleworth E.E., Smedley C., Houston S.A., Fenton T.M., Levison S., Mann E.R., Travis M.A. Human monocytes and macrophages regulate immune tolerance via integrin αvβ8–mediated TGFβ activation. Journal of Experimental Medicine, 2018, vol. 215, no. 11, pp. 2725-2736. https://doi.org/10.1084/jem.20171491

12. Malenica I., Adam J., Corgnac S. Integrin-αV-mediated activation of TGF-β regulates anti-tumour CD8 T cell immunity and response to PD-1 blockade. Nature Communications, 2021, vol. 12, no. 1, pp. 5209. https://doi.org/10.1038/s41467-021-25322-y

13. Mayanagi T., Morita T., Hayashi K., Fukumoto K., Sobue K. Glucocorticoid receptor-mediated expression of caldesmon regulates cell migration via the reorganization of the actin cytoskeleton. Journal of Biological Chemistry, 2008, vol. 283, no. 45, pp. 31183-31196. https://doi.org/10.1074/jbc.m801606200

14. Nalluri S.M., O'Connor J.W., Virgi G.A., Stewart S.E., Ye D., Gomez E.W. TGFβ1‐ induced expression of caldesmon mediates epithelial–mesenchymal transition. Cytoskeleton, 2018, vol. 75, no. 5, pp. 201-212. https://doi.org/10.1002/cm.21437

15. Sani S., Messe M., Fuchs Q. Biological relevance of RGD‐integrin subtype‐ specific ligands in cancer. ChemBioChem., 2021, vol. 22, no. 7, pp. 1151-1160. https://doi.org/10.1002/cbic.202000626

16. Sarmazdeh M.R., Sankaran B., Radisky D., Radisky E. Engineering Tissue Inhibitor of Metalloproteinases‐1 (TIMP‐1) as a Selective Inhibitor of Matrix Metalloproteinase‐3 (MMP‐3) for Therapeutic Targeting. The FASEB Journal, 2018, no. 32, pp. 798. https://doi.org/10.1096/fasebj.2018.32.1_supplement.798.7

17. Slack R.J., Macdonald S.J.F., Roper J.A., Jenkins R.G., Hatley R.J.D. Emerging therapeutic opportunities for integrin inhibitors. Nature Reviews Drug Discovery, 2022, vol. 21, no. 1, pp. 60-78. https://doi.org/10.1038/s41573-021-00284-4

18. Takawale A., Zhang P., Patel V.B., Wang X., Oudit G., Kassiri Z. Tissue inhibitor of matrix metalloproteinase-1 promotes myocardial fibrosis by mediating CD63–integrin β1 interaction. Hypertension, 2017, vol. 69, no. 6, pp. 1092-1103. https://doi.org/10.1161/hypertensionaha.117.09045

19. Villeneuve J., Belloc F., Hugues M., Freyburger G., Solanilla A., Lepreux S., Ripoche J. Tissue inhibitor of matrix metalloproteinase‐1 reduces phosphatidylserine exposure on activated and aged platelets. British Journal of Haematology, 2010, vol. 149, no. 2, pp. 302-306. https://doi.org/10.1111/j.1365-2141.2009.08047.x

20. Yokouchi K., Numaguchi Y., Kubota R., Ishii M., Imai H., Murakami R., Ogawa Y., Kondo T., Okumura K., Ingber D.E., Murohara T. l-Caldesmon regulates proliferation and migration of vascular smooth muscle cells and inhibits neointimal formation after angioplasty. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, vol. 26, no. 10, pp. 2231-2237. https://doi.org/10.1161/01.atv.0000239441.29687.97

21.